Monopar Therapeutics (MNPR) Equity Average: 2018-2020
Historic Equity Average for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $14.8 million.
- Monopar Therapeutics' Equity Average rose 204.01% to $14.8 million in Q3 2020 from the same period last year, while for Sep 2020 it was $14.8 million, marking a year-over-year increase of 204.01%. This contributed to the annual value of $9.8 million for FY2019, which is 18.19% up from last year.
- Latest data reveals that Monopar Therapeutics reported Equity Average of $14.8 million as of Q3 2020, which was up 20.76% from $12.3 million recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Equity Average peaked at $14.8 million during Q3 2020, and registered a low of $4.9 million during Q3 2019.
- Its 3-year average for Equity Average is $8.9 million, with a median of $8.5 million in 2018.
- As far as peak fluctuations go, Monopar Therapeutics' Equity Average crashed by 37.88% in 2019, and later soared by 204.01% in 2020.
- Monopar Therapeutics' Equity Average (Quarterly) stood at $7.2 million in 2018, then rose by 19.03% to $8.6 million in 2019, then spiked by 204.01% to $14.8 million in 2020.
- Its Equity Average was $14.8 million in Q3 2020, compared to $12.3 million in Q2 2020 and $12.5 million in Q1 2020.